TABLE 2
FROM:
Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions
A Y L Ho, S Devereux, G J Mufti and A Pagliuca
BACK TO ARTICLETable 2. Transplant and clinical follow-up
| Patient no. | Donor/source/sex | CD34 dose (kg) | CMV recipient/donor | Neutrophil recovery (days) | Platelet recovery (days) | CT findings pre-transplant | CT response post-transplant |
|---|---|---|---|---|---|---|---|
| 1 | Sibling/PBSC/f | 5.66  106
| Pos/pos | 11 | 10 | PR | D+77SD |
| D+138SD | |||||||
| D+323CR | |||||||
| 2 | Sibling/PBSC/m | 2.9 106
| Pos/pos | 20 | 23 | PR | D+99SD |
| D+185SD | |||||||
| D+246SD | |||||||
| D+574PD | |||||||
| 3 | Sibling/PBSC/f | 6.95 106
| Pos/pos | 11 | 12 | CR | D+56CR |
| D+168CR | |||||||
| D+382CR | |||||||
| 4 | VUD/BM/f | 3.45 106
| Neg/pos | 29 | 50 | CR | D+180CR |
| D+356CR | |||||||
| 5 | Sibling/PBSC/m | 4.76 106
| Pos/neg | 12 | 12 | CR | D+120CR |
| D+294CR |
CR, complete remission; PR, partial remission; PD, progressive disease; SD, stable disease; VUD, volunteer unrelated donor; PBSC, peripheral blood stem cells; BM, bone marrow; neutrophil recovery defined as neutrophils >0.5 109/l for 
2 consecutive days; platelet recovery defined as unsupported platelet count > 20 109/l for 2 consecutive days.
